Clinical Trials Logo
  1. Home
  2. Chronic Kidney Disease
  3. NCT01000545
  4. Details
NCT01000545 Clinical Trial

The Efficacy and Safety Study of Sulodexide in Filipino Diabetic Patients With Chronic Kidney Disease

Chronic Kidney Disease Clinical Trial

— DEFINE  

Official title:
The Efficacy and Safety of Sulodexide in Filipino Diabetic Patients With Chronic Kidney Disease: A Randomized Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT01000545
Other study ID # SLD-CKD-001
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received October 22, 2009
Last updated October 29, 2009
Start date November 2009
Est. completion date December 2012

Study information
Verified date October 2009
Source Corbridge Group Philippines, Inc.
Contact Arlene C Crisostomo, M.D., MSc.
Phone 639189004532
Email arlene_crisostomo_md@yahoo.com
Is FDA regulated No
Health authority Philippines: Bureau of Food and DrugsPhilippines: Philippine Council for Health Research and Development
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the effect and safety of Sulodexide in Filipino patients with Chronic Kidney Disease (CKD).

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 1508
Est. completion date December 2012
Est. primary completion date January 2011
Accepts healthy volunteers No
Gender Both
Age group 19 Years and older
Eligibility Inclusion Criteria:

- Type 2 diabetes mellitus

- positive 2 of 3 ACR > 300 mg/g or 24h urine protein or albumin collection > 300 mg/d in the absence of urinary tract infection

- serum creatinine 1.3 - 3 mg/dl in women and 1.5 - 3 mg/dl in men

Exclusion Criteria:

- age of onset of DM \< 18 years

- + renal disease like non-DM renal disease

- + CV diseases such as UA, MI, CABG

- + CVA or TIA within last 6 months

- untreated UTI

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Sulodexide
SLX 500 LRU, SLX 1000 LRU, SLX 2000 LRU per day to be taken orally for 12 months.
• placebo capsules
8 soft-gel capsules per day to be taken orally for 12 months

Locations
Country Name City State
Philippines Holy Child Hospital Dumaguete City
Philippines Mary Mediatrix Medical Center Lipa City Batangas
Philippines Victoriano R. Potenciano Medical Center Mandaluyong City
Philippines Metropolitan Medical Center Manila
Philippines Rizal Private Clinics Metro Manila Rizal
Philippines Manila Adventist Medical Center Pasay City
Philippines The Medical City Pasig City

Sponsors (2)
Lead Sponsor Collaborator
Corbridge Group Philippines, Inc. Alfa Wassermann S.p.A.

Country where clinical trial is conducted

Philippines, 

Outcome
Type Measure Description Time frame Safety issue
Primary macroalbuminuria and serum creatinine 52 weeks Yes
Secondary adverse events 52 weeks Yes
See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Completed NCT05318014 - Low-protein Formula Supplements in Chronic Kidney Disease N/A
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4